SureTrader SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 9/2/2015 11:12:06 PM - Followers: 42 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
Wiki
GALT News: Current Report Filing (8-k) 09/02/2015 08:49:09 AM
GALT News: Statement of Changes in Beneficial Ownership (4) 08/12/2015 05:04:14 PM
GALT News: Quarterly Report (10-q) 08/10/2015 08:13:28 AM
GALT News: Current Report Filing (8-k) 08/10/2015 07:51:56 AM
GALT News: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID® to Monitor Patients with Cirrhosis As... 08/03/2015 08:00:00 AM
PostSubject
#2091   Wow... That works out to an average of thefamilyman 09/02/15 11:12:06 PM
#2090   Clinical Trial To Establish Efficacy Of Gr-Md-02 In candeeman 09/02/15 11:05:51 AM
#2089   Yeah. Maybe you should change your name to Darwinian 08/31/15 11:04:51 PM
#2088   Great Upside Potential for $GALT GalacticGreen 08/31/15 09:27:25 PM
#2087   I have a tough time believing Czirr. IRAHopeful 08/31/15 04:33:53 PM
#2086   That's what I've been hoping. I hope it Darwinian 08/31/15 03:06:51 PM
#2085   I recall Czzir stating they hope the shorter Adi2 08/31/15 01:40:43 PM
#2084   I got a response. It was about what Darwinian 08/19/15 02:02:38 PM
#2083   The reply was from Shlevin, the COO. IRAHopeful 08/18/15 10:58:02 AM
#2082   Tell your friend to closely analyze each of thefamilyman 08/17/15 08:37:15 PM
#2081   -Why not just submit the question through the IRAHopeful 08/17/15 01:03:53 PM
#2080   Can you post the article or a link? jmh0602 08/17/15 10:34:12 AM
#2079   Sent a message through the website about the Darwinian 08/16/15 02:46:08 PM
#2078   Great news articale and was spot on 5 mad money fund 08/16/15 01:13:35 PM
#2077   There is another option. They could get the thefamilyman 08/15/15 09:20:55 PM
#2076   Yes the CX trial is recruiting DirectionalDriller 08/15/15 08:38:16 PM
#2075   Where did you get your information because it jmh0602 08/15/15 08:06:17 PM
#2074   Yes familyman it is very tight timing, anymore DirectionalDriller 08/15/15 08:04:23 PM
#2073   That schedule looks very tight for the GALTW thefamilyman 08/15/15 07:35:11 PM
#2072   The FX trial is not recruiting yet & DirectionalDriller 08/15/15 06:04:59 PM
#2071   http://news.investors.com/081315-766405-icpt-stock-falls-on-morgan-stanley-repor jmh0602 08/13/15 02:21:15 PM
#2070   I'm not seeing it on Scottrade or NASDAQ. thefamilyman 08/13/15 02:17:06 PM
#2069   Ahh...thanks. I'll look it up. GALT and ICPT Darwinian 08/13/15 01:00:12 PM
#2068   Morgan Stanley gave a bad recommendation for ICPT jmh0602 08/13/15 12:45:45 PM
#2067   Good news about the patent extension but I'm Darwinian 08/13/15 11:35:15 AM
#2066   GALT Receives USPTO Notice of Allowance for Pectin-Derived candeeman 08/13/15 08:47:47 AM
#2065   -Why not just submit the question through the biotech2010 08/12/15 02:13:18 PM
#2064   Thank you. I guess my question needs to thefamilyman 08/12/15 11:36:12 AM
#2063   FamilyMan: Please see below. 45-60 sites. Tesla1 08/12/15 11:19:05 AM
#2062   Galectin Therapeutics's buy rating reiterated at MLV & candeeman 08/12/15 10:10:10 AM
#2061   That would be good news. However, the thefamilyman 08/11/15 08:48:19 PM
#2060   There is plenty of potential good news for Tesla1 08/11/15 06:47:18 PM
#2059   FamilyMan: the "CX" trial is slated for 45 Tesla1 08/11/15 06:39:12 PM
#2058   this pos ticker pans out exactly like a penny... oldsport 08/11/15 03:58:19 PM
#2057   I don't think it would "delay the study" thefamilyman 08/11/15 11:37:57 AM
#2056   I converted all of my GALTW to GALT biotech2010 08/11/15 08:07:48 AM
#2055   I'm really hoping (at this point "banking") on Darwinian 08/10/15 06:24:04 PM
#2054   No new shares is good news. But thefamilyman 08/10/15 03:27:12 PM
#2053   No Shares Sold by Company during Q2, let's biotech2010 08/10/15 10:47:20 AM
#2052   I vote for you. Let us know IRAHopeful 08/05/15 02:21:34 PM
#2051   CEO perspectives - signed up for the newsletter jmh0602 08/05/15 12:55:31 PM
#2050   somebody should call up cramer and ask him oldsport 08/05/15 09:24:35 AM
#2049   A little more info on the recent news. IRAHopeful 08/04/15 07:24:53 PM
#2048   be a good sport... cheer up... oldsport 07/29/15 03:32:32 PM
#2047   There are 5 trials going on now. IRAHopeful 07/29/15 02:55:58 PM
#2046   Are we supposed to get any updates on poonch1ne 07/28/15 11:38:14 PM
#2045   Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., Darwinian 07/16/15 12:01:14 AM
#2044   Last week there were 9 Form 4s filed. thefamilyman 07/12/15 11:31:58 PM
#2043   Galectin initiates enrollment in mid-stage trial of GR-MD-02 candeeman 07/01/15 08:52:46 PM
#2042   I've given up being concerned about the share biotech2010 07/01/15 09:45:54 AM
PostSubject